Announcements
Projects
Orgs
Project
Articles 6
Votes 0
Pfizer.com

Authors 1

Pfizer
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility - Pfizer
5d
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer - Pfizer
~2y
U.S. FDA Approves Pfizer's VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) - Pfizer
~2y
Pfizer's ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma - Pfizer
>2y
FDA Approves Pfizer's LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata - Pfizer
>2y
Pfizer's TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval - Pfizer
>2y